This bulletin discusses the pharmacological management of chronic obstructive pulmonary disease (COPD), with a focus on inhaled therapies and supporting the implementation of national guidance.
It discusses a number of prescribing considerations that affect choice of treatment, exacerbations, self-management and safety.
